GKOS Glaukos Corporation

  1. Stocks
  2. Healthcare
  3. NYSE: GKOS

Price (delayed)

$238.61

Market cap

$14.12B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.95

Enterprise value

$14.06B

?
Relative Growth: Rel. Growth: 66
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 22

Glaukos ( www.glaukos.com ) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos ...

Highlights
The revenue has grown by 47% YoY and by 13% from the previous quarter
The company's gross profit rose by 24% YoY and by 20% QoQ
Glaukos's net income has shrunk by 94% YoY but it has increased by 10% QoQ
Glaukos's EPS has plunged by 93% YoY but it has increased by 10% from the previous quarter
The quick ratio has contracted by 10% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.glaukos.com
Peers: IART ICUI

Key stats

What are the main financial stats of GKOS

GKOS stock price

How has the Glaukos stock price performed over time
Intraday
0.43%
1 week
33.85%
1 month
45.72%
1 year
170.93%
YTD
111.33%
QTD
45.33%

Financial performance

How have Glaukos's revenue and profit performed over time
Revenue
$690.33M
Gross profit
$447.18M
Operating income
-$176.16M
Net income
-$169.8M
Gross margin
64.8%
Net margin
-24.6%
GKOS's operating income has shrunk by 99% YoY but it is up by 9% QoQ
Glaukos's net income has shrunk by 94% YoY but it has increased by 10% QoQ
The revenue has grown by 47% YoY and by 13% from the previous quarter
The company's operating margin fell by 36% YoY but it rose by 19% QoQ

Price vs fundamentals

How does GKOS's price correlate with its fundamentals

Growth

What is Glaukos's growth rate over time

Valuation

What is Glaukos stock price valuation
P/E
N/A
P/B
19.62
P/S
20.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.37
Glaukos's EPS has plunged by 93% YoY but it has increased by 10% from the previous quarter
The price to book (P/B) is 155% more than the 5-year quarterly average of 7.7 and 75% more than the last 4 quarters average of 11.2
Glaukos's equity has decreased by 7% YoY but it has increased by 5% QoQ
The P/S is 66% higher than the 5-year quarterly average of 12.3 and 58% higher than the last 4 quarters average of 12.9
The revenue has grown by 47% YoY and by 13% from the previous quarter

Efficiency

How efficient is Glaukos business performance
The ROE has plunged by 118% YoY but it has grown by 8% from the previous quarter
The return on assets has dropped by 107% year-on-year but it is up by 9% since the previous quarter
The ROIC has dropped by 91% year-on-year but it is up by 10% since the previous quarter
Glaukos's ROS has decreased by 41% YoY but it has increased by 20% from the previous quarter

Dividends

What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GKOS.

Financial health

How did Glaukos financials performed over time
The company's total liabilities rose by 14% YoY and by 10% QoQ
GKOS's current ratio is down by 12% year-on-year and by 9% since the previous quarter
The debt is 86% lower than the equity
The debt to equity has contracted by 7% from the previous quarter
Glaukos's equity has decreased by 7% YoY but it has increased by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.